Source link : https://www.newshealth.biz/health-news/early-stage-glp-1-win-in-obesity-an-argument-for-bmis-value-insulin-supply-issues/
Participants in a phase I trial lost a placebo-adjusted 6.1% of their body weight after 4 weeks of treatment with the investigational oral GLP-1 receptor agonist CT-996, Roche announced. JAMA published a review on medications for obesity. BMI is still “a valuable method” for defining obesity despite its flaws, argued authors of an Annals of […]
Author : News Health
Publish date : 2024-07-23 17:47:52
Copyright for syndicated content belongs to the linked Source.
Categories